Results 1 to 10 of about 20,235 (188)
Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up? [PDF]
Western Journal of Emergency Medicine, 2020 Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as ...
Tony Zitek, Ramsey Ataya, Isabel Brea
doaj +3 more sources
Comparative effectiveness of Tenecteplase and Alteplase for ischemic stroke: real-world data from a stroke center [PDF]
BMC NeurologyBackground Tenecteplase (TNK) and Alteplase (rt-PA) are intravenous thrombolytics used in acute ischemic stroke (AIS). While Alteplase has long been the standard of care, TNK is now also approved for AIS by both the EMA and FDA.
Toska Maxhuni +10 more
doaj +2 more sources
Comparative effectiveness and safety of tenecteplase versus alteplase for intravenous thrombolysis in acute ischemic stroke: a retrospective study [PDF]
Frontiers in NeurologyBackgroundTenecteplase has been proposed as a practical alternative to alteplase for intravenous thrombolysis in acute ischemic stroke. Although randomised trials have demonstrated noninferiority, data from real-world comparative cohorts remain limited ...
Weili Zhao +4 more
doaj +2 more sources
Analysis of hemorrhagic transformation and intracerebral hemorrhage under combination therapy with alteplase and antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database. [PDF]
PLoS ONERecombinant tissue-type plasminogen activators (rtPA) effectively dissolve blood clots and improve symptoms in patients with acute ischemic stroke and myocardial infraction.
Tsuyoshi Nakai +6 more
doaj +2 more sources
Frontiers in Neurology, 2023 Background and purposePrevious studies have stimulated debates on low-dose alteplase administration in acute ischemic stroke (AIS) among the Asian population.
Jiawen Xu +7 more
doaj +1 more source
Frontiers in Neurology, 2021 Background: Intravenous thrombolysis with alteplase benefits eligible patients with acute ischemic stroke. However, in some countries such as China, alteplase may be too expensive for low-income patients, and also for regions with low economic ...
Rongrong Zhang +11 more
doaj +1 more source
Tenecteplase Thrombolysis in Posterior Circulation Stroke
Frontiers in Neurology, 2021 One in five ischaemic strokes affects the posterior circulation. Basilar artery occlusion is a type of posterior circulation stroke associated with a high risk of disability and mortality.
Fana Alemseged, Bruce C. V. Campbell
doaj +1 more source
Frontiers in Neurology, 2023 BackgroundThe optimal dose of tenecteplase vs. alteplase for acute ischemic stroke (AIS) has yet to be established. Therefore, we included the latest randomized controlled trials (RCT) to assess the efficacy and safety of different doses of tenecteplase ...
Huo Liang +8 more
doaj +1 more source
Therapeutic Advances in Neurological Disorders, 2023 Background: Whether low-dose alteplase is similar to standard-dose bridging alteplase prior to endovascular mechanical thrombectomy in patients with acute ischemic stroke (AIS) remains uncertain.
Wei Zheng +10 more
doaj +1 more source
Frontiers in Neurology, 2021 Background: To date, the role of bridging intravenous thrombolysis before mechanical thrombectomy (MTE) is controversial but still recommended in eligible patients.
Duy Ton Mai +18 more
doaj +1 more source